International Clinical Trial: Efficacy of Voriconazole for Primary Prophylaxis of Invasive Pulmonary Aspergillosis in Acute Myeloid Leukemia Patients Receiving Chemotherapy

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (TCTR20260301004) titled 'Efficacy of Voriconazole for Primary Prophylaxis of Invasive Pulmonary Aspergillosis in Acute Myeloid Leukemia Patients Receiving Chemotherapy' on March 1.

Study Type: Interventional

Study Design: Randomized

Primary Sponsor: Siam Pharmaceutical Co., Ltd.

Condition: Invasive Pulmonary Aspergillosis (IPA) between patients receiving voriconazole and those not receiving it, within 60 days after patients with Acute Myeloid Leukemia (AML) receive chemotherapy. Invasive pulmonary aspergillosis acute myeloid leukemia voriconazole primary antifungal prophylaxis Invasive pulmonary aspergillosis acute myeloid leukemia...